James F. Oliviero III

Filings by James F. Oliviero III span 3 companies, the busiest being Keryx Biopharmaceuticals Inc, Checkpoint Therapeutics, Inc. and Nuvectis Pharma, Inc. Over a trading history stretching from 14 August 2008 to 12 June 2025, the count stands at 104 filings.

Market trades split into 2 purchases (€8,861) and 60 sales (€12.2M). The net balance comes to €12.2M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 29 share grants and 8 option exercises. 2025 to date brings no purchases and 3 sales.

On 12 June 2025 came the latest disclosure, a share grant in Nuvectis Pharma, Inc. The clock since the last published purchase (23 June 2009) now reads 6,332 days. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.